Connect Biopharma Presents CBP-201 Target Engagement and Immune Modulation Data at the Society for Investigative Dermatology Annual Conference
SAN DIEGO, CA and TAICANG, China, May 17, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research will be presenting data describing the immunological profile of CBP-201 based on preclinical experiments, demonstrating reductions in clinically validated biomarkers of Th2-driven inflammation. Additionally, the Company will be reporting distinct binding epitopes, higher binding affinity, and increased potency demonstrating improved target engagement properties with CBP-201 compared to dupilumab. The data will be presented in a poster at the Society for Investigative Dermatology Annual Conference, May 18-21 at the Oregon Convention Center, Portland, Oregon.
Poster Presentation Details
Title: CBP-201, a novel and differentiated IL-4Ra targeting antibody being evaluated in Th2 inflammatory diseases
Presented by: Paul A. Smith, VP, Discovery Biology, Connect Biopharma
The poster is available on the Presentations and Publications section of the Company’s website: https://www.connectbiopharm.com/our-science/presentations-and-publications/.
About Atopic Dermatitis
About Connect Biopharma Holdings Limited
With operations in the United States and China, Connect Biopharma is building a rich global pipeline of molecules and antibodies targeting several aspects of T cell biology. For additional information, please visit www.connectbiopharm.com.